v3.26.1
Fair Value Measurements and Marketable Equity Securities - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended
Aug. 31, 2024
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Aug. 30, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Contingent consideration classified as equity, fair value disclosure   $ 3,817,000   $ 4,984,000    
Aggregate proceeds from sale of marketable equity securities   0 $ 8,316,000      
Marketable equity securities outstanding   $ 117,902,000   150,211,000    
Investment In Recursion Pharmaceuticals Class A Common Stock [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Investment in equity securities at fair value sold number of shares   0 737,466      
Weighted average price per share of investment sold   $ 11.28        
Aggregate proceeds from sale of marketable equity securities   $ 8,300,000        
Fair Value, Inputs, Level 1 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Contingent consideration classified as equity, fair value disclosure   3,817,000   4,984,000    
Fair Value, Inputs, Level 2 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Contingent consideration classified as equity, fair value disclosure   0   0    
Fair Value, Inputs, Level 3 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Contingent consideration classified as equity, fair value disclosure   0   $ 0    
Gain or loss due to change in fair value for assets and liabilities measured at fair value using significant unobservable inputs (Level 3)   $ 0 $ 0      
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Class Of Warrant Share Issued   9,218,800       9,218,800
Common stock purchase price $ 18,400,000          
Purchase of additional shares of common stock 3,500,000          
Purchase of additional shares of common stock value $ 17,700,000          
Outstanding common stock percentage 20.00%          
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 1.5  
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 2.5  
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Class Of Warrant Excisable At Cash   4,609,400        
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Class Of Warrant Excisable At Cash         4,609,400  
Deep 6 Acquisition [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Number of held back shares in connection with business acquisition   13,614        
Paige AI Inc [Member]            
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]            
Number of held back shares in connection with business acquisition   70,792